Literature DB >> 6362572

Experimental studies on the mechanism of benoxaprofen photoreactions.

B Ljunggren, M Bjellerup, H Möller.   

Abstract

Benoxaprofen (BP), a non-steroidal antiphlogistic drug causing skin and nail photoreactions, has been evaluated for photoactivity using three experimental techniques. In vivo in the mouse, BP was phototoxic in doses of 25 mg/kg in combination with UV-A 54J. The phototoxic potency could be confirmed in vitro with the Candida albicans test. In vitro, using photohemolysis, BP showed a dose-dependent activity causing 40% hemolysis at a concentration of about 25 micrograms/ml with UV-A. Also, small UV-B doses caused red cell lysis with a moderate BP concentration. Pre-irradiation experiments showed that UV-A, but not UV-B, photoproducts could account for some of the activity. The action spectrum of BP photoactivity lies mainly in the UV-A, but may also extend into UV-B. Compared with chlorpromazine in vivo and in vitro, and with doxycycline in vivo, BP showed intermediate phototoxic activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6362572     DOI: 10.1007/bf00417205

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  14 in total

1.  A SIMPLE MICROBIOLOGICAL METHOD FOR DEMONSTRATING PHOTOTOXIC COMPOUNDS.

Authors:  F DANIELS
Journal:  J Invest Dermatol       Date:  1965-04       Impact factor: 8.551

2.  Cellular mechanisms of chlorpromazine photosensitivity.

Authors:  B E Johnson
Journal:  Proc R Soc Med       Date:  1974-09

3.  Red blood cell hemolysis by photosensitizing compounds.

Authors:  G Kahn; B Fleischaker
Journal:  J Invest Dermatol       Date:  1971-02       Impact factor: 8.551

4.  The phototoxic effects of benoxaprofen and their management and prevention.

Authors:  M C Greist; I I Ozols; A S Ridolfo; J C Muus
Journal:  Eur J Rheumatol Inflamm       Date:  1982

5.  Phototoxic reaction to chlorpromazine as studied with the quantitative mouse tail technique.

Authors:  B Ljunggren; H Möller
Journal:  Acta Derm Venereol       Date:  1976       Impact factor: 4.437

6.  Pharmacokinetic studies of benoxaprofen after therapeutic doses with a review of related pharmacokinetic and metabolic studies.

Authors:  J F Nash; R H Carmichael; A S Ridolfo; C T Spradlin
Journal:  J Rheumatol Suppl       Date:  1980

7.  An update on long-term efficacy and safety with benoxaprofen.

Authors:  W M Mikulaschek
Journal:  Eur J Rheumatol Inflamm       Date:  1982

8.  Phototoxicity to benoxaprofen.

Authors:  A M Kligman; K H Kaidbey
Journal:  Eur J Rheumatol Inflamm       Date:  1982

9.  Benoxaprofen: side-effect profile in 300 patients.

Authors:  J P Halsey; N Cardoe
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-08

10.  Long-term safety of benoxaprofen.

Authors:  W M Mikulaschek
Journal:  J Rheumatol Suppl       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.